Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) and Aurora Cannabis (NASDAQ:ACB – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.
Institutional & Insider Ownership
47.6% of Aurora Cannabis shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Recordati Industria Chimica E Farmaceutica and Aurora Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Recordati Industria Chimica E Farmaceutica | 18.38% | 33.73% | 12.76% |
| Aurora Cannabis | -32.26% | 4.37% | 3.45% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Recordati Industria Chimica E Farmaceutica | 0 | 1 | 0 | 1 | 3.00 |
| Aurora Cannabis | 1 | 1 | 1 | 1 | 2.50 |
Volatility and Risk
Recordati Industria Chimica E Farmaceutica has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Valuation & Earnings
This table compares Recordati Industria Chimica E Farmaceutica and Aurora Cannabis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Recordati Industria Chimica E Farmaceutica | $2.96 billion | 4.04 | $501.92 million | $2.80 | 20.71 |
| Aurora Cannabis | $314.07 million | 0.85 | -$88.13 million | ($1.41) | -2.91 |
Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.
Summary
Recordati Industria Chimica E Farmaceutica beats Aurora Cannabis on 9 of the 13 factors compared between the two stocks.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
About Aurora Cannabis
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
